Showing 1161-1170 of 1236 results for "".
- GPX4 Modulator Shows Early Promise in First-in-Human Studyhttps://modernaesthetics.com/news/gpx4-modulator-shows-early-promise-in-first-in-human-study/2486474/A novel topical therapy targeting cellular senescence showed early biologic activity across multiple dermatologic conditions in a Phase 1 clinical trial, according to data presented by Frederick Beddingfield III, MD, PhD, FAAD, at the Dermatology Innovation Forum during the American Academy of De
- AAD 2026: Revance to Showcase Expanding Aesthetics Portfoliohttps://modernaesthetics.com/news/aad-2026-revance-to-showcase-expanding-aesthetics-portfolio/2486383/Revance Therapeutics Inc. announced it will showcase its expanding portfolio of aesthetics, regenerative medicine, and consumer skincare products at the 2026 American Academy of Dermatology (AAD) Annual Meeting, scheduled for March 26–31 in Denver, Colorado. The company plans a series of in-booth
- New Hydrobiome Serum Targets Skin Barrier and Microbiome Balancehttps://modernaesthetics.com/news/new-hydrobiome-serum-targets-skin-barrier-and-microbiome-balance/2486308/Epicutis has announced the launch of Hydrobiome Serum, a new addition to its clinical skincare portfolio developed in partnership with Signum Biosciences. The formulation is designed for patients with blemish-prone or congested skin and emphasizes microbiome balance and barrier support rather tha
- CO2 Laser Plus CBT Shows Benefit in Postadolescent Acne Excoriée Case Serieshttps://modernaesthetics.com/news/co2-laser-plus-cbt-shows-benefit-in-postadolescent-acne-excoriee-case-series/2485795/A combined psychodermatologic approach integrating CO₂ laser ablation and cognitive-behavioral therapy (CBT) was associated with clinical improvement in patients with treatment-resistant postadolescent acne excoriée, according to a case series published in the February 2026 issue of Journal o
- Lynch Regenerative Medicine Names General Counsel, CMOhttps://modernaesthetics.com/news/lynch-regenerative-medicine-names-general-counsel-cmo/2485740/Lynch Regenerative Medicine (LRM), a regenerative medicine company focused on platelet-derived growth factor–based therapies, has named Madison Dini as General Counsel and Chad Lindemann as Chief Marketing Officer. According to the company, Dini will lead legal, compliance, and corporate g
- Octane Aesthetics Tech Forum: Panelists Discuss Innovation in Hair Loss Delivery, Regulationhttps://modernaesthetics.com/news/octane-aesthetics-tech-forum-panelists-discuss-innovation-in-hair-loss-delivery-regulation/2485561/The future of hair restoration may be rooted in regenerative science, but panelists at the Octane Aesthetics Tech Forum agree: the real-world success of these advances hinges on how treatments are delivered and how they’re regulated. Speaking during the “Hiding in the Shadows of H
- CollPlant Launches US Logistics Hub to Support North American Growthhttps://modernaesthetics.com/news/collplant-launches-us-logistics-hub-to-support-north-american-growth/2484120/CollPlant Biotechnologies has expanded its North American operations through a new partnership with a US-based logistics hub, the company announced. The center, expected to become operational this quarter, will support the growing distribution needs for CollPlant’s recombinant human collagen (rhC
- Daxxify® Surpasses 1 Million Vials Distributed in US Aesthetic Markethttps://modernaesthetics.com/news/daxxify-surpasses-1-million-vials-distributed-in-us-aesthetic-market/2483419/Revance Therapeutics has announced the distribution of more than 1 million vials of daxibotulinumtoxinA-lanm (Daxxify®) for aesthetic use in the United States, marking a notable milestone 3 years after the product received US Food and Drug Administration (FDA) approval. According to a pres
- AMI Pharm Advances AYP-101 to Phase 3 Testing for Noninflammatory Fat Reductionhttps://modernaesthetics.com/news/ami-pharm-advances-ayp-101-to-phase-3-testing-for-noninflammatory-fat-reduction/2476093/AMI Pharm has initiated a pivotal Phase 3 clinical trial of AYP-101, an investigational injectable for the treatment of submental fat. The study will evaluate the efficacy and safety of the agent, which is designed to reduce localized fat with fewer inflammatory side effects than current therapie
- New Collaboration Enhances Precision and Patient Engagement in Post-Weight-Loss Treatmentshttps://modernaesthetics.com/news/new-collaboration-enhances-precision-and-patient-engagement-in-post-weight-loss-treatments/2475376/MNML Aesthetics announced a partnership with ShapeScale to integrate 3D body imaging into its MNML Tone Method, a multi-modality body contouring protocol. The collaboration aims to enhance clinical precision and patient engagement in aesthetic practices, particularly in post-weight-loss body tran